HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind comparative trial of astemizole and terfenadine for the treatment of hay fever.

Abstract
Astemizole, a new long acting and non sedative antihistamine, and Terfenadine, an H1 antagonist widely used, were compared in a randomized double-blind study over 4 weeks in 55 patients suffering from hay fever. The clinical symptoms were recorded daily from each patient on a 4-point scale from 0 = none to 3 = severe. After 2 weeks of therapy and at the end, the total clinical score was evaluated and both the investigator and the patient made an overall assessment of the therapeutic effect. Both drugs were effective in reducing nasal and ocular symptoms, but the clinical response tended to be better with Astemizole than Terfenadine. The difference between the two drugs, however, was statistically significant (p less than 0.05) only after 2 weeks of treatment. Some side effects, including drowsiness, were observed with similar incidence in both treatment groups. Astemizole appears to be a simple, effective and safe therapy for hay fever.
AuthorsC Troise, S Voltolini, P Cilli, A C Negrini
JournalAllergie et immunologie (Allerg Immunol (Paris)) Vol. 21 Issue 10 Pg. 396-8, 400 (Dec 1989) ISSN: 0397-9148 [Print] France
PMID2576206 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Benzhydryl Compounds
  • Benzimidazoles
  • Histamine H1 Antagonists
  • Terfenadine
  • Astemizole
Topics
  • Astemizole
  • Benzhydryl Compounds (therapeutic use)
  • Benzimidazoles (therapeutic use)
  • Double-Blind Method
  • Histamine H1 Antagonists (therapeutic use)
  • Humans
  • Rhinitis, Allergic, Seasonal (diagnosis, drug therapy)
  • Terfenadine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: